疫苗诱导免疫性血栓性血小板减少症患者血浆显示纤溶潜力增加并增强组织型纤溶酶原激活剂而非尿激酶介导的纤溶酶原激活
该研究比较了10例疫苗诱导免疫性血栓性血小板减少症(VITT)患者、10例接种后静脉血栓栓塞但无VITT(VTE-no VITT)患者和14例健康接种对照者的血浆纤溶活性。VITT患者基线纤溶酶-抗纤溶酶(PAP)复合物水平较对照组和VTE-no VITT组高约7倍(P < .0001),并出现α2-抗纤溶酶消耗和纤维蛋白原溶解。VITT血浆经组织型纤溶酶原激活剂(tPA)体外刺激后PAP水平显著高于其他组,但经尿激酶刺激后无此差异。
要点
- VITT患者基线PAP复合物水平较对照和VTE-no VITT组高约7倍(P < .0001)。
- VITT血浆显示α2-抗纤溶酶消耗和纤维蛋白原溶解,符合高纤溶状态。
- VITT血浆经tPA体外刺激后PAP水平显著高于其他组,经尿激酶刺激后无差异。
核心结论
- VITT患者存在明显的高纤溶状态,表现为PAP显著升高、α2-抗纤溶酶消耗和纤维蛋白原溶解。
- VITT患者血浆中似乎存在一种未知的血浆辅因子,选择性增强tPA介导的纤溶酶原激活。
研究设计与样本
- 研究比较了10例VITT患者、10例VTE-no VITT患者和14例健康接种对照者的血浆。
- 采用酶联免疫吸附试验和/或蛋白质印迹法评估PAP复合物、纤溶酶原和α2-抗纤溶酶水平。
- 通过定量基线和体外50 nM tPA或尿激酶刺激5分钟后的PAP水平评估纤溶能力。
主要发现
- 对照者和VTE-no VITT个体的基线PAP复合物水平相似,但VITT患者血浆PAP水平高约7倍(P < .0001)。
- VITT样本显示α2-抗纤溶酶消耗和纤维蛋白原溶解,符合高纤溶状态。
- VITT血浆经tPA体外处理后PAP水平显著高于其他组,但经尿激酶处理后无显著差异。
- 向VTE-no VITT血浆中加入D-二聚体未能增强tPA诱导的PAP水平,表明VITT中tPA增强效应并非由D-二聚体介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare complication of adenovirus vector-based COVID-19 vaccines. VITT is associated with markedly raised levels of D-dimer; yet, how VITT modulates the fibrinolytic system is unknown. OBJECTIVES: We aimed to compare changes in fibrinolytic activity in plasma from patients with VITT, patients diagnosed with venous thromboembolism (VTE) after vaccination but without VITT (VTE-no VITT), and healthy vaccinated controls. METHODS: Plasma levels of plasmin-antiplasmin (PAP) complexes, plasminogen, and alpha-2-antiplasmin (α2AP) from 10 patients with VITT, 10 patients with VTE-no VITT, and 14 healthy vaccinated controls were evaluated by enzyme-linked immunosorbent assay and/or Western blotting. Fibrinolytic capacity was evaluated by quantitating PAP levels at baseline and after ex vivo plasma stimulation with 50-nM tissue-type plasminogen activator (tPA) or urokinase for 5 minutes. RESULTS: Baseline PAP complex levels in control and VTE-no VITT individuals were similar but were ∼7-fold higher in plasma from patients with VITT (P < .0001). VITT samples also revealed consumption of α2AP and fibrinogenolysis consistent with a hyperfibrinolytic state. Of interest, VITT plasma produced significantly higher PAP levels after ex vivo treatment with tPA, but not urokinase, compared to the other groups, indicative of increased fibrinolytic potential. This was not due to D-dimer as addition of D-dimer to VTE-no VITT plasma failed to potentiate tPA-induced PAP levels. CONCLUSION: A marked hyperfibrinolytic state occurs in patients with VITT, evidenced by marked elevations in PAP, α2AP consumption, and fibrinogenolysis. An unidentified plasma cofactor that selectively potentiates tPA-mediated plasminogen activation also appears to exist in the plasma of patients with VITT.
引用
- Keragala CB, McFadyen JD, Ho H, et al. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation. J Thromb Haemost. 2023. PMID: 37944898. doi:10.1016/j.jtha.2023.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。